
<!DOCTYPE html>
<html lang="en">
<head>
<meta charset="UTF-8">
<title>AASLD Practice Guidance on risk stratification and management of portal hypertension and varices in cirrhosis</title>
<style>

<style>
body {
    font-family: 'Segoe UI', Tahoma, Geneva, Verdana, sans-serif;
    background: linear-gradient(135deg, #f0f4ff, #fafafa);
    color: #2c2c2c;
    padding: 40px;
}

/* Mindmap container */
.mindmap {
    max-width: 900px;
    margin: auto;
    font-size: 16px;
    line-height: 1.7;
}

.mindmap ul {
    margin: 0.5em 0 1em 1em;
    padding-left: 1.5em;
    list-style: disc;
    color: #555;
    font-size: 0.95em;
    font-weight: 400;
    line-height: 1.6;
}

.mindmap li::marker {
    color: #a855f7; /* prettier bullets */
}

.mindmap li {
    margin-bottom: 6px;
    padding-left: 4px;
}


/* Collapsible sections */
.mindmap details {
    border-left: 4px solid #8b5cf6;
    background: #ffffff;
    margin: 15px 0;
    padding: 16px 20px;
    border-radius: 16px;
    box-shadow: 0 4px 12px rgba(139, 92, 246, 0.12);
    transition: all 0.3s ease;
    position: relative;
}

/* Hover glow */
.mindmap details:hover {
    box-shadow: 0 6px 18px rgba(139, 92, 246, 0.2);
    background: linear-gradient(135deg, #ffffff, #f3f0ff);
}

/* Summary styling */
.mindmap summary {
    cursor: pointer;
    font-size: 1.15em;
    font-weight: 600;
    list-style: none;
    position: relative;
    padding-left: 28px;
    color: #4c1d95;
}

/* Custom arrow */
.mindmap summary::before {
    content: "▶";
    position: absolute;
    left: 0;
    top: 2px;
    transition: transform 0.3s ease;
    font-size: 1em;
    color: #7c3aed;
}

.mindmap details[open] > summary::before {
    transform: rotate(90deg);
}

/* Titles */
.mindmap summary strong {
    display: block;
    font-size: 1.3em;
    color: #4c1d95;
}

.mindmap summary em {
    font-style: normal;
    color: #6b21a8;
    font-size: 0.95em;
}

/* Description bullets */
.mindmap ul {
    padding-left: 22px;
    margin-top: 10px;
    margin-bottom: 12px;
}

.mindmap li {
    margin-bottom: 6px;
    font-size: 0.97em;
    color: #444;
    list-style-type: disc;
    position: relative;
    padding-left: 4px;
}

/* Nesting indent style */
.mindmap details > div > details {
    margin-left: 20px;
    border-color: #a855f7;
    background: #f9f5ff;
}

/* Fade-in effect */
.mindmap details[open] > div {
    animation: fadeIn 0.3s ease-in;
}

/* Description box */
.mindmap .desc-box {
    background: #fdfcff;
    border: 1px solid #e5d9fb;
    border-left: 4px solid #c084fc;
    padding: 4px 6px;
    margin: 12px 0 18px 0;
    border-radius: 12px;
    box-shadow: 0 1px 3px rgba(160, 104, 255, 0.06);
    transition: background 0.3s ease;
}

.mindmap .desc-box:hover {
    background: #f9f4ff;
}


button {
    background-color: #7c3aed;
    color: white;
    border: none;
    padding: 10px 16px;
    margin: 0 6px;
    font-size: 1em;
    border-radius: 8px;
    cursor: pointer;
    transition: background 0.3s ease;
}
button:hover {
    background-color: #6b21a8;
}


@keyframes fadeIn {
    from { opacity: 0; transform: translateY(-3px); }
    to { opacity: 1; transform: translateY(0); }
}


#level-controls button {
    background-color: rgba(124, 58, 237, 0.7); /* semi-transparent purple */
    color: white;
    border: none;
    padding: 8px 14px;
    margin: 0 6px;
    font-size: 1em;
    border-radius: 8px;
    cursor: pointer;
    transition: background 0.3s ease, transform 0.2s;
}

#level-controls button:hover {
    background-color: rgba(107, 33, 168, 0.85); /* slightly darker on hover */
    transform: scale(1.05);
}

#level-controls {
    position: fixed;
    bottom: 20px;
    left: 50%;
    transform: translateX(-50%);
    background: rgba(124, 58, 237, 0.1);
    padding: 8px 14px;
    border-radius: 12px;
    box-shadow: 0 4px 10px rgba(0, 0, 0, 0.1);
    z-index: 9999;
    backdrop-filter: blur(6px);
    cursor: move; /* shows move cursor */
}

</style>




</style>
</head>
<body>
<div id="level-controls" onmousedown="dragElement(this)">
    <button onclick="setMindmapLevel(1)">Level 1</button>
    <button onclick="setMindmapLevel(2)">Level 2</button>
    <button onclick="setMindmapLevel(3)">Level 3</button>
</div>

<div class="mindmap">

    <div class="mindmap">
        
        <details>
            <summary><strong>AASLD Practice Guidance on risk stratification and management of portal hypertension and varices in cirrhosis</strong></summary>
            <div>
                <ul><li>Authors: David E. Kaplan, Cristina Ripoll, Maja Thiele, Brett E. Fortune, Douglas A. Simonetto, Guadalupe Garcia-Tsao, Jaime Bosch</li><li>Journal: Hepatology</li><li>Publication Date: 2024</li><li>DOI: 10.1097/HEP.0000000000000647</li><li>Purpose: Coalesce best practice recommendations for identification and management of portal hypertension (PH) and varices in chronic liver disease.</li><li>Updates and expands on the 2017 AASLD Practice Guidance.</li><li>Significant changes based on the 7th Baveno consensus conference (October 2021).</li></ul>
                
        <details>
            <summary><strong>Knowledge Test</strong></summary>
            <div>
                <ul><li>1. What HVPG value defines clinically significant portal hypertension (CSPH)?</li><li>2. What non-selective beta-blocker is preferred for management of PH according to this guidance?</li><li>3. What are the three main clinical stages of cirrhosis?</li><li>4. What LSM value by TE generally rules in cACLD?</li><li>5. What is the recommended hemoglobin target during initial resuscitation of acute variceal hemorrhage (AVH) in the absence of comorbidities?</li></ul>
                
            </div>
        </details>
        
        <details>
            <summary><strong>Purpose and Scope of the Guidance</strong></summary>
            <div>
                <ul><li>Coalesce best practice recommendations for:</li><li>Identification of portal hypertension (PH).</li><li>Prevention of initial hepatic decompensation.</li><li>Management of acute variceal hemorrhage (AVH).</li><li>Reduction of risk of recurrent variceal hemorrhage in chronic liver disease.</li></ul>
                
        <details>
            <summary><strong>Updates from Previous Guidance</strong></summary>
            <div>
                <ul><li>Updates and expands on the 2017 AASLD Practice Guidance.</li><li>Based on the 7th Baveno consensus conference (October 2021).</li><li>Significant changes include recognition of cACLD, noninvasive assessment of CSPH, and early NSBB therapy.</li></ul>
                
        <details>
            <summary><strong>Key Changes</strong></summary>
            <div>
                <ul><li>Recognition of compensated advanced chronic liver disease (cACLD).</li><li>Codification of noninvasive assessments to identify clinically significant portal hypertension (CSPH).</li><li>Recommendation of early utilization of nonselective beta-blocker (NSBB) therapy to decrease risk of cirrhosis decompensation.</li></ul>
                
            </div>
        </details>
        
        <details>
            <summary><strong>Additional Topics</strong></summary>
            <div>
                <ul><li>Potential future pharmacotherapy options for PH.</li><li>Role of preemptive TIPS in AVH.</li><li>Management of cardiofundal varices.</li><li>New topics: portal hypertensive gastropathy (PHG), endoscopy prior to TEE, and antineoplastic therapy.</li></ul>
                
            </div>
        </details>
        
            </div>
        </details>
        
        <details>
            <summary><strong>Exclusions</strong></summary>
            <div>
                <ul><li>Does not focus on ascites (covered in AASLD Practice Guidance on ascites and related complications).</li><li>Does not focus on vascular causes of PH.</li><li>Harmonizes with AASLD Practice Guidance on TIPS, Variceal Embolization, and Retrograde Transvenous Obliteration.</li></ul>
                
            </div>
        </details>
        
        <details>
            <summary><strong>Target Population</strong></summary>
            <div>
                <ul><li>Specifically addresses PH in adults.</li><li>Future guidance on the management of cirrhosis in children from the AASLD anticipated.</li></ul>
                
            </div>
        </details>
        
        <details>
            <summary><strong>Guidance vs. Guidelines</strong></summary>
            <div>
                <ul><li>Provides a data-supported approach to prevention and management of PH and varices.</li><li>Developed by consensus of an expert panel based on comprehensive review and analysis of the literature.</li></ul>
                
            </div>
        </details>
        
            </div>
        </details>
        
        <details>
            <summary><strong>Context of PH in Cirrhosis</strong></summary>
            <div>
                <ul><li>Definition of PH: Portal vein pressure is proportional to splanchnic blood inflow and resistance.</li><li>PH in cirrhosis: Defined as a portocaval pressure gradient &gt;5 mm Hg.</li><li>Initial pathogenic mechanism: Increase in resistance to portal flow, followed by increase in portal venous inflow.</li></ul>
                
        <details>
            <summary><strong>Classification of PH</strong></summary>
            <div>
                <ul><li>Based on site of increased resistance:</li><li>Prehepatic: Resistance occurs in the portal vein prior to entry into the liver.</li><li>Intrahepatic: Resistance occurs within the liver.</li><li>Posthepatic: Resistance occurs after blood exits the liver through the hepatic veins.</li></ul>
                
        <details>
            <summary><strong>Intrahepatic Subclassification</strong></summary>
            <div>
                <ul><li>Presinusoidal: Affects the portal triad.</li><li>Sinusoidal: Affects the hepatic sinusoids (e.g., cirrhosis).</li><li>Postsinusoidal: Affects the efferent (central) vein.</li></ul>
                
            </div>
        </details>
        
        <details>
            <summary><strong>Common Causes</strong></summary>
            <div>
                <ul><li>Most common cause: Cirrhosis.</li><li>Second most common cause: Portal vein thrombosis.</li></ul>
                
            </div>
        </details>
        
            </div>
        </details>
        
        <details>
            <summary><strong>Stages of Cirrhosis</strong></summary>
            <div>
                <ul><li>Histological evaluation: Fibrosis stages 0-2 (early), F3 (advanced), F4 (cirrhotic).</li><li>Clinical presentation: Compensated and decompensated.</li></ul>
                
        <details>
            <summary><strong>Decompensation Definition</strong></summary>
            <div>
                <ul><li>Defined by clinically overt complications of PH:</li><li>Overt ascites.</li><li>Variceal hemorrhage.</li><li>Overt hepatic encephalopathy (HE).</li></ul>
                
            </div>
        </details>
        
        <details>
            <summary><strong>Survival Rates</strong></summary>
            <div>
                <ul><li>Compensated cirrhosis: Median survival &gt;12 years.</li><li>Decompensated cirrhosis: Median survival &lt;1.5 years.</li></ul>
                
            </div>
        </details>
        
            </div>
        </details>
        
        <details>
            <summary><strong>Clinically Significant Portal Hypertension (CSPH)</strong></summary>
            <div>
                <ul><li>Defined by portal pressure gradients ≥10 mm Hg.</li><li>Surrogate markers: Gastroesophageal varices on endoscopy and/or portosystemic collaterals on imaging.</li><li>Compensated cirrhosis subclassified into those without and with CSPH.</li></ul>
                
            </div>
        </details>
        
        <details>
            <summary><strong>Further Decompensation</strong></summary>
            <div>
                <ul><li>Successive complications (recurrent variceal hemorrhage, refractory ascites, hepatorenal syndrome, SBP, jaundice) → higher mortality rates.</li><li>Designated as “further decompensation”.</li></ul>
                
            </div>
        </details>
        
        <details>
            <summary><strong>Advanced Chronic Liver Disease (ACLD)</strong></summary>
            <div>
                <ul><li>Denotes patients likely close to cirrhosis based on LSM and platelet count.</li><li>cACLD: ACLD without prior decompensation.</li><li>LSM by TE &lt;10 kPa rules out cACLD; ≥15 kPa rules in cACLD.</li></ul>
                
        <details>
            <summary><strong>CSPH Rule-In</strong></summary>
            <div>
                <ul><li>LSM by TE &gt;25 kPa (in non-obese patients).</li><li>Platelet counts used with intermediate LSM values following the “Rule of Five”.</li></ul>
                
            </div>
        </details>
        
        <details>
            <summary><strong>LSM Limitations</strong></summary>
            <div>
                <ul><li>LSM by TE should not be used for clinical decision-making without confirmation of high study quality and trained personnel.</li><li>Other elastography technologies need validated cutoffs.</li></ul>
                
            </div>
        </details>
        
            </div>
        </details>
        
        <details>
            <summary><strong>Resolution of PH</strong></summary>
            <div>
                <ul><li>Reductions in portal pressure (pharmacological therapy or TIPS) decrease risk of decompensation and may improve survival.</li><li>Elimination of mechanical obstruction and/or control of underlying liver disease may reduce portal pressure.</li></ul>
                
        <details>
            <summary><strong>Clinical Recompensation</strong></summary>
            <div>
                <ul><li>Resolution of ascites and/or HE no longer requiring specific therapy.</li><li>Absence of recurrent variceal hemorrhage for &gt;12 months.</li><li>Stable improvement of liver function tests (albumin, INR, bilirubin).</li></ul>
                
            </div>
        </details>
        
            </div>
        </details>
        
            </div>
        </details>
        
        <details>
            <summary><strong>Pathophysiological Bases of Pharmacological Therapy</strong></summary>
            <div>
                <ul><li>Cirrhosis: Fibrous tissue and nodule formation → ↑ intrahepatic vascular resistance → ↑ portal pressure.</li><li>Splanchnic vasodilation augments portal blood flow, further raising portal pressure.</li><li>Dynamic component (↑ intrahepatic vascular tone, ↓ nitric oxide bioavailability) accounts for ≈30% of ↑ intrahepatic resistance.</li></ul>
                
        <details>
            <summary><strong>NSBBs for PH</strong></summary>
            <div>
                <ul><li>Beneficial effects: ↓ portal pressure through ↓ portal and collateral blood flow.</li><li>Mechanism: ↓ cardiac output (β-1 blockade) and splanchnic arterial vasoconstriction (β-2 blockade).</li></ul>
                
            </div>
        </details>
        
        <details>
            <summary><strong>Carvedilol</strong></summary>
            <div>
                <ul><li>NSBB w/ anti-alpha-1-adrenergic activity + facilitates nitric oxide release → intrahepatic vasodilation.</li><li>More pronounced ↓ in HVPG than traditional NSBBs (propranolol, nadolol).</li><li>Dosing: Start 6.25 mg/day, ↑ to 12.5 mg/day after 2-3 days if tolerated; ↓ to 6.25 mg daily if not tolerated or SBP &lt;90 mm Hg.</li></ul>
                
        <details>
            <summary><strong>Carvedilol Advantages</strong></summary>
            <div>
                <ul><li>Greater reduction of portal pressure.</li><li>Trend for better tolerance.</li><li>Simpler administration.</li><li>Possibility of preventing ascites.</li><li>Potential survival advantage.</li></ul>
                
            </div>
        </details>
        
            </div>
        </details>
        
        <details>
            <summary><strong>Experimental Pharmacological Targets</strong></summary>
            <div>
                <ul><li>Novel agents (statins, cGT activators/stimulators, anticoagulants, anti-inflammatory agents) target endothelial dysfunction, microthromboses, and/or inflammation.</li><li>Statins: Significant effects on HVPG reduction, improved survival after acute variceal bleeding.</li></ul>
                
        <details>
            <summary><strong>Statins</strong></summary>
            <div>
                <ul><li>Retrospective data: ↓ rate of progression to cirrhosis, decompensation, and death; greater ↓ in HCC risk w/ lipophilic statins (simvastatin, atorvastatin).</li><li>Simvastatin: Do not use &gt;20 mg/day in decompensated cirrhosis.</li><li>Atorvastatin: Use low doses (10-20 mg) pending additional data.</li></ul>
                
            </div>
        </details>
        
            </div>
        </details>
        
        <details>
            <summary><strong>Guidance Statements</strong></summary>
            <div>
                <ul><li>Carvedilol is recommended as the preferred NSBB for the treatment of PH in patients with cirrhosis.</li><li>Recommended maintenance dosage of carvedilol is 6.25–12.5 mg/day.</li><li>In patients with concomitant arterial hypertension or cardiac disease, the dose of carvedilol may be further increased to address nonhepatic indications.</li></ul>
                
            </div>
        </details>
        
            </div>
        </details>
        
        <details>
            <summary><strong>Diagnosis and Monitoring</strong></summary>
            <div>
                <ul><li>Hepatic vein wedge pressure measurements: Indirectly measures portal pressure via transjugular catheter in hepatic vein.</li><li>Wedged hepatic vein pressure (WHVP) ≈ portal vein pressure in cirrhosis.</li><li>HVPG = WHVP - free hepatic vein pressure (FHVP).</li></ul>
                
        <details>
            <summary><strong>HVPG Accuracy</strong></summary>
            <div>
                <ul><li>Increased by:</li><li>Using balloon catheters.</li><li>Obtaining triplicate measurements.</li><li>Following measurement conventions.</li></ul>
                
            </div>
        </details>
        
        <details>
            <summary><strong>HVPG Prognostic Information</strong></summary>
            <div>
                <ul><li>Valuable in:</li><li>Compensated and decompensated cirrhosis at baseline.</li><li>Response to vasoactive drug therapy.</li><li>After elimination of the cause of cirrhosis.</li><li>Prior to resection operation for HCC.</li><li>Prior to any major operation in patients with cirrhosis.</li></ul>
                
            </div>
        </details>
        
        <details>
            <summary><strong>HVPG Limitations</strong></summary>
            <div>
                <ul><li>Inaccurate in presinusoidal PH (noncirrhotic primary biliary cholangitis, granulomatous diseases, portosinusoidal vascular disorder).</li><li>May be inaccurate in some patients with NASH, but values retain prognostic significance.</li><li>Moderately invasive, small risks, requires expertise.</li></ul>
                
            </div>
        </details>
        
        <details>
            <summary><strong>Noninvasive Detection of CSPH</strong></summary>
            <div>
                <ul><li>Conventional imaging (US, CT, MRI) has limited role.</li><li>Specific imaging surrogate markers: Collaterals, ascites.</li><li>Doppler-based sonographic assessments: Moderate sensitivity and specificity, not widely applied.</li></ul>
                
        <details>
            <summary><strong>LSM and Platelet Count</strong></summary>
            <div>
                <ul><li>Best validated noninvasive staging system for compensated cirrhosis.</li><li>“Rule of Five” quantifies risk of decompensation and liver-related mortality, defines cACLD, CSPH, and threshold for screening upper endoscopy.</li></ul>
                
            </div>
        </details>
        
        <details>
            <summary><strong>LSM Cautions</strong></summary>
            <div>
                <ul><li>Caution in applying “Rule of Five” in patients with obesity and NAFLD/NASH, ALT &gt;3x ULN, and primary sclerosing cholangitis.</li><li>LSM &gt; 25 kPa has &gt;90% PPV for CSPH in chronic viral hepatitis, alcohol-associated liver disease, and lean NAFLD.</li></ul>
                
            </div>
        </details>
        
        <details>
            <summary><strong>CSPH Estimation</strong></summary>
            <div>
                <ul><li>Most robust estimation: Combination LSM (by TE) and platelet count.</li><li>CSPH presumed: LSM &gt; 25 kPa; LSM 20-25 kPa and platelets &lt; 150 K/mm3; LSM 15-20 kPA and platelets &lt; 110 K/mm3.</li><li>CSPH excluded: LSM &lt; 15 kPa + platelets &gt; 150 k/mm3.</li></ul>
                
            </div>
        </details>
        
        <details>
            <summary><strong>Other Markers</strong></summary>
            <div>
                <ul><li>Liver stiffness-spleen size-to-platelet ratio &gt; 2.65 corresponds to a risk of CSPH above 80%.</li><li>SSM by TE shows stronger correlation with HVPG than LSM when HVPG &gt; 10 mm Hg.</li><li>SSM ≤46 kPa may rule out varices needing treatment.</li></ul>
                
            </div>
        </details>
        
        <details>
            <summary><strong>Non-TE Elastography</strong></summary>
            <div>
                <ul><li>MRE, pSWE, and two-dimensional shear wave elastography less well validated, subject to cross-manufacturer variability.</li><li>MRE &lt;3.5 kPa generally rules out cACLD, and ≥5.0 kPa rules in cACLD.</li><li>pSWE: LSM cutoff &gt; 2.17 m/s may identify CSPH.</li></ul>
                
            </div>
        </details>
        
            </div>
        </details>
        
        <details>
            <summary><strong>Monitoring Development of CSPH</strong></summary>
            <div>
                <ul><li>Longitudinal studies of LSM by TE suggest:</li><li>Monitoring progression in patients with initial LSM 5-10 kPa (repeat LSM every 2-3 years).</li><li>Confirming initial LSM suggestive of cACLD.</li><li>Monitoring progression in patients with initial LSM diagnostic of cACLD without CSPH (repeat LSM by TE and platelet count annually).</li></ul>
                
            </div>
        </details>
        
        <details>
            <summary><strong>LSM Changes</strong></summary>
            <div>
                <ul><li>A ≥20% increase or decrease in LSM by TE appears to correlate with clinically relevant deteriorations or improvement.</li><li>Monitoring LSM in cACLD should only be performed if a 20% change (increase or decrease) would alter patient management.</li></ul>
                
            </div>
        </details>
        
        <details>
            <summary><strong>Monitoring Changes in HVPG</strong></summary>
            <div>
                <ul><li>No role of LSM or SSM for monitoring HVPG response to NSBB.</li><li>SSM has been proposed as a better marker of changes in PH, but MRE-measured SSM did not correlate with acute NSBB response in one small study.</li></ul>
                
            </div>
        </details>
        
        <details>
            <summary><strong>Guidance Statements</strong></summary>
            <div>
                <ul><li>Hepatic Venous Pressure Gradient (HVPG) measurement is the gold-standard method to assess portal pressure in patients with cirrhosis.</li><li>Clinically significant portal hypertension (CSPH) is defined as HVPG ≥10 mm Hg.</li><li>HVPG may underestimate portal pressure in some patients with obesity and NASH-related cirrhosis.</li><li>The presence of clinical decompensation, of gastroesophageal varices on endoscopy, or portosystemic collaterals or hepatofugal flow on imaging is sufficient to diagnose CSPH.</li><li>CSPH can be noninvasively identified by LSM by vibration-controlled TE (or non-TE approaches when validated cutoffs exist) and platelet count.</li><li>Annual LSM by TE (or non-TE approaches when validated cutoffs exist) and serum platelet counts may provide prognostic information in patients with cACLD without baseline CSPH in whom the underlying etiologies of cirrhosis remain active/uncontrolled.</li></ul>
                
            </div>
        </details>
        
            </div>
        </details>
        
        <details>
            <summary><strong>Stage-Specific Management of PH</strong></summary>
            <div>
                <ul><li>Compensated cirrhosis without CSPH but with mild PH (HVPG 6-9 mm Hg): Patients with cACLD subcategorized according to presence/absence of CSPH.</li><li>All patients undergo regular imaging (every 6 months) to screen for HCC and portal vein thrombosis.</li></ul>
                
        <details>
            <summary><strong>Management</strong></summary>
            <div>
                <ul><li>Patients without CSPH: Special attention to imaging evidence indicating development of CSPH.</li><li>Serial assessment for need for EGD to identify high-risk varices remains important.</li><li>Use of LSM measurement in combination with platelet count (Baveno VI criteria) can identify patients in whom screening EGD can be avoided.</li></ul>
                
            </div>
        </details>
        
        <details>
            <summary><strong>Beta-Blockers</strong></summary>
            <div>
                <ul><li>Treatment with beta-blockers in compensated cirrhosis without CSPH is not indicated.</li><li>Suppression or cure of etiological cause of liver disease, lifestyle optimization, and control of comorbidities attenuate and/or reverse progression.</li></ul>
                
            </div>
        </details>
        
        <details>
            <summary><strong>Other Medications</strong></summary>
            <div>
                <ul><li>NAFLD/NASH: Obeticholic acid (contraindicated with PH), lanifibranor, and semaglutide have shown early promise in reducing fibrosis in patients who are noncirrhotic.</li><li>Statins: Possible benefits on cACLD.</li><li>Metformin: Could be safe and may reduce HVPG, incidence of HCC, and decompensation in compensated cirrhosis.</li><li>Low-dose aspirin: Might also reduce incidence of HCC and liver-related mortality in patients with chronic hepatitis B and C.</li></ul>
                
            </div>
        </details>
        
        <details>
            <summary><strong>Guidance Statements</strong></summary>
            <div>
                <ul><li>Use of NSBBs in patients with cirrhosis without CSPH is not recommended for prevention of decompensation.</li><li>Lifestyle modification and treatment of underlying liver disease should be prioritized to prevent progression to CSPH and decompensation.</li></ul>
                
            </div>
        </details>
        
            </div>
        </details>
        
        <details>
            <summary><strong>Compensated Cirrhosis with Proven or Likely CSPH (HVPG ≥10 mm Hg)</strong></summary>
            <div>
                <ul><li>Patients at increased risk of decompensation.</li><li>Other methods to detect CSPH can be used: Presence of portosystemic collaterals, TE can identify patients with CSPH.</li></ul>
                
        <details>
            <summary><strong>NSBB Initiation</strong></summary>
            <div>
                <ul><li>Data from one prospective trial and a systematic meta-analysis provide support for initiation of NSBB to prevent decompensation in cACLD with CSPH.</li><li>PREDESCI study: NSBB manifested significantly lower risk of decompensation (HR, 0.51; 95% CI, 0.26–0.97), predominantly a lower risk of developing ascites.</li></ul>
                
            </div>
        </details>
        
        <details>
            <summary><strong>Surveillance Endoscopy</strong></summary>
            <div>
                <ul><li>In absence of imaging surrogates of CSPH, in which TE is not available, patients with cACLD should undergo surveillance endoscopy.</li><li>Patients with cACLD without varices who have ongoing liver injury should have endoscopy repeated every 2 years, and those without varices in whom liver injury is quiescent should undergo variceal surveillance every 3 years.</li></ul>
                
            </div>
        </details>
        
        <details>
            <summary><strong>Guidance Statements</strong></summary>
            <div>
                <ul><li>In patients with compensated cirrhosis and CSPH, the goal of therapy is to prevent the development of clinical decompensation.</li><li>NSBBs (preferably carvedilol 12.5 mg/day) should be considered for patients with cACLD with CSPH to prevent decompensation.</li><li>NSBBs should not be administered to patients with cACLD and evidence of CSPH with asthma, advanced heart block, and bradyarrhythmias, and caution should be used in patients with relative contraindications.</li><li>Patients with cACLD and evidence of CSPH (by endoscopy, TE, HVPG or imaging) who are candidates for NSBB should be considered for treatment with NSBB (in the absence of contraindications) to prevent hepatic decompensation, which would also obviate the need for further screening endoscopy.</li><li>Where TE is not available to diagnose CSPH, when empiric NSBB are contraindicated or not considered due to prior intolerance, endoscopic surveillance of all patients with cirrhosis is recommended.</li><li>Where TE is not available, screening endoscopy is not necessary in patients on non-selective beta-blocker therapy; the need for screening endoscopy can be also obviated in some patients on a selective beta-blocker by switching therapy to a non-selective beta-blocker after discussion with the prescribing clinician.</li></ul>
                
            </div>
        </details>
        
            </div>
        </details>
        
        <details>
            <summary><strong>Compensated Cirrhosis with a Contraindication to or Intolerance of Beta-Blockers</strong></summary>
            <div>
                <ul><li>Patients have no further therapeutic options to avoid clinical decompensation other than control of the underlying disease.</li><li>Patients with a standard indication for statin therapy should continue treatment, and statins should not be discouraged when indicated.</li></ul>
                
        <details>
            <summary><strong>Endoscopic Surveillance</strong></summary>
            <div>
                <ul><li>In patient with cACLD with CSPH for whom beta-blockers cannot be safely administered, endoscopic surveillance should be initiated with an intent to prevent first variceal hemorrhage (primary prophylaxis) through prophylactic endoscopic band ligation of high-risk varices.</li><li>Performance of an endoscopy every 2 years is recommended; however, if cause of the liver disease is under control, endoscopic surveillance may be done every 3 years.</li></ul>
                
            </div>
        </details>
        
        <details>
            <summary><strong>Endoscopic Variceal Ligation (EVL)</strong></summary>
            <div>
                <ul><li>If EVL is selected for primary prophylaxis of high-risk varices, EVL should be repeated until all varices are eradicated.</li><li>Intervals between endoscopies evaluated in clinical trials for primary and secondary prophylaxis have ranged from 1 to 8 weeks.</li><li>After eradication, periodic endoscopy should be repeated every 6–12 months.</li></ul>
                
            </div>
        </details>
        
        <details>
            <summary><strong>TIPS</strong></summary>
            <div>
                <ul><li>Prophylactic TIPS to prevent first variceal hemorrhage in the setting of compensated cirrhosis with high-risk varices should not be recommended.</li></ul>
                
            </div>
        </details>
        
        <details>
            <summary><strong>Guidance Statements</strong></summary>
            <div>
                <ul><li>Patients with compensated cirrhosis and CSPH without varices who have contraindications or intolerance to beta-blockers should be screened for varices needing treatment with surveillance endoscopy every 2 years when the underlying disease remains uncontrolled and every 3 years when controlled.</li><li>Patients with compensated cirrhosis and CSPH with varices that have not bled who have contraindications or intolerance to beta-blockers should be screened for varices needing treatment with surveillance endoscopy every 1 year when the underlying disease remains uncontrolled and every 2 years when controlled.</li><li>Primary prophylaxis with EVL should be performed in patients with cACLD and CSPH and high-risk varices that cannot receive NSBBs.</li><li>Band ligation should be repeated every 2–4 weeks until obliteration and then endoscopy repeated at 6 months and then every 12 months to assess for reappearance of varices requiring additional treatment.</li><li>TIPS should not be used for the prevention of decompensation of cirrhosis or as primary prophylaxis for variceal hemorrhage.</li></ul>
                
            </div>
        </details>
        
            </div>
        </details>
        
        <details>
            <summary><strong>Primary Prophylaxis to Prevent Variceal Hemorrhage in dACLD</strong></summary>
            <div>
                <ul><li>Patients who have decompensated cirrhosis by definition have CSPH.</li><li>Increasing CTP class, variceal size, and presence of variceal red wale marks are associated with an increase in the risk of a first variceal hemorrhage.</li></ul>
                
        <details>
            <summary><strong>Management</strong></summary>
            <div>
                <ul><li>Patients with high-risk varices should undergo primary prophylaxis to prevent variceal bleeding.</li><li>If high-risk varices are small, the only method that is technically feasible is the administration of NSBB.</li><li>If the high-risk varices are large, both NSBB as well as EVL are possible approaches; however, a recent systematic review with network meta-analysis showed that EVL is associated with a higher risk of complications and higher mortality than NSBB.</li></ul>
                
            </div>
        </details>
        
        <details>
            <summary><strong>NSBB Safety</strong></summary>
            <div>
                <ul><li>The safety of NSBB among patients who have ascites and refractory ascites has been an issue of extensive discussion.</li><li>However, several studies have shown that NSBB in patients with ascites and even refractory ascites are safe and potentially beneficial.</li><li>Low systolic blood pressure (&lt; 90 mm Hg) may attenuate the survival advantage associated with NSBB use.</li></ul>
                
            </div>
        </details>
        
        <details>
            <summary><strong>Guidance Statements</strong></summary>
            <div>
                <ul><li>Patients with decompensated cirrhosis not taking NSBBs who have never bled from varices should undergo annual endoscopic screening.</li><li>If high-risk varices are detected, NSBBs or endoscopic band ligation are recommended; preference is given to NSBBs (including carvedilol) because of benefits beyond prevention of variceal hemorrhage.</li><li>NSBBs should be dose reduced or discontinued in patients who develop persistently low systolic arterial pressure &lt;90 mm Hg or severe adverse effects. NSBB discontinuation should prompt endoscopic evaluation for presence of high-risk varices requiring band ligation.</li></ul>
                
            </div>
        </details>
        
            </div>
        </details>
        
        <details>
            <summary><strong>AVH, Initial Bleed</strong></summary>
            <div>
                <ul><li>AVH remains an emergent complication of cirrhosis and requires timely and effective management to prevent short-term mortality.</li><li>6-week mortality still ranges from 10% to 15%.</li><li>Hemorrhage results from variceal wall rupture because of increased wall tension.</li></ul>
                
        <details>
            <summary><strong>Management</strong></summary>
            <div>
                <ul><li>Maintain adequate systemic organ perfusion and oxygenation while achieving hemostasis but avoidance of worsening portal pressure.</li><li>Patients with known or suspected history of advanced liver disease should be managed as having a portal hypertensive-related source until endoscopic confirmation.</li><li>Placement of adequate intravenous access and airway assessment are initial measures for resuscitation.</li></ul>
                
            </div>
        </details>
        
        <details>
            <summary><strong>Vasoactive Therapy and Antimicrobial Prophylaxis</strong></summary>
            <div>
                <ul><li>Vasoactive therapy should be initiated immediately on presentation and maintained for 2–5 days.</li><li>Intravenous antimicrobials are recommended until stability for discharge or 5 days, whichever is shorter, in the absence of active infection.</li><li>Intravenous ceftriaxone dosed at 1 g every 24 hours is often preferred because of high rates of quinolone resistance.</li></ul>
                
            </div>
        </details>
        
        <details>
            <summary><strong>Transfusion Goals</strong></summary>
            <div>
                <ul><li>Packed red blood cell transfusion goals should be restricted for a target hemoglobin of about 7 g/dL in the absence of comorbidities.</li><li>Coagulation parameters such as international normalized ratio do not predict hemostatic dysfunction, and liberal transfusion of frozen plasma and other blood products should be avoided.</li></ul>
                
            </div>
        </details>
        
        <details>
            <summary><strong>Endoscopic Evaluation</strong></summary>
            <div>
                <ul><li>Timely upper endoscopic evaluation should be performed (within 12 hours of AVH presentation) to determine source of bleeding and therapy.</li><li>EVL, repeated after discharge every 2–4 weeks until variceal obliteration, should be the standard endoscopy approach for esophageal varices.</li><li>Intravenous erythromycin 125–250 mg given 30–120 minutes before endoscopy has been shown to facilitate visualization and therapy.</li></ul>
                
            </div>
        </details>
        
        <details>
            <summary><strong>Preemptive TIPS</strong></summary>
            <div>
                <ul><li>For specific patients who are high risk and have AVH, “early” or preemptive TIPS improves both bleeding control as well as survival in most studies.</li><li>Specifically, patients with CTP class B score &gt; 7 with active bleeding on endoscopy and CTP class C score 10–13 should undergo TIPS within 24–72 hours of initial endoscopy.</li></ul>
                
            </div>
        </details>
        
        <details>
            <summary><strong>Post-Hemorrhage Management</strong></summary>
            <div>
                <ul><li>Once hemostasis, hemodynamic stability, and normal mentation have been restored, oral nutrition must be started immediately to avoid malnutrition.</li><li>Proton pump inhibitors should be discontinued in the absence of absolute indications because of increased risk of infection and encephalopathy.</li><li>NSBBs can be introduced once patients can tolerate oral intake.</li></ul>
                
            </div>
        </details>
        
        <details>
            <summary><strong>Guidance Statements</strong></summary>
            <div>
                <ul><li>All patients with known or suspected cirrhosis presenting with acute gastrointestinal bleeding should be initiated on vasoactive therapy and intravenous antibacterial therapy as soon as possible.</li><li>If portal hypertensive bleeding is confirmed at endoscopy, vasoactive therapy should be continued for 2–5 days.</li><li>Intravenous antibacterial treatment should be tailored to local resistance patterns and patient allergies.</li><li>Packed red blood cell transfusions should target a hemoglobin ~7 g/dL unless higher targets required related to comorbid conditions.</li><li>Fresh frozen plasma and platelet transfusions should not be administered based on international normalized ratio or platelet count targets, respectively.</li><li>Upper endoscopy should be performed within 12 hours of presentation with AVH.</li><li>If esophageal variceal bleeding is confirmed, EVL should be performed.</li><li>In patients with CTP class B score &gt; 7 and active bleeding on endoscopy or CTP class C score 10–13, preemptive TIPS creation should be recommended in absence of absolute contraindications to TIPS.</li><li>In patients presenting with AVH who do not undergo TIPS, NSBB should be initiated at discontinuation of vasoactive therapy.</li><li>Covered expandable esophageal stents or balloon tamponade should be considered in patients with uncontrolled AVH as a bridge to TIPS.</li><li>TIPS should be considered in patients with uncontrolled AVH (“salvage” TIPS) or who rebleed despite vasoactive therapy and EVL (“rescue” TIPS).</li><li>Enteral feeding should be started once AVH episode has been controlled.</li><li>Proton pump inhibitors should be discontinued once AVH has been confirmed as the bleeding source in the absence of other specific indications.</li></ul>
                
            </div>
        </details>
        
            </div>
        </details>
        
        <details>
            <summary><strong>Prevention of Recurrent Hemorrhage After Initial Bleeding</strong></summary>
            <div>
                <ul><li>Patients are at high risk of rebleeding (up to 60% at 1 y without prophylaxis).</li><li>Secondary prophylaxis to prevent rebleeding should be instituted immediately after control of the index bleed, within 7 days from admission.</li></ul>
                
        <details>
            <summary><strong>Management</strong></summary>
            <div>
                <ul><li>Patients who underwent preemptive TIPS, no further measures are required.</li><li>Those without preemptive TIPS should receive secondary prophylaxis with NSBBs and endoscopic band ligation.</li><li>When compared with EVL alone, the combination of EVL and NSBB reduced rebleeding in all categories of patients and improved survival in patients with CTP class B and C.</li></ul>
                
            </div>
        </details>
        
        <details>
            <summary><strong>NSBBs</strong></summary>
            <div>
                <ul><li>Propranolol, nadolol, and carvedilol may be used for secondary prophylaxis; carvedilol has greater effects on HVPG reduction but a higher potential to cause systemic hypotension.</li><li>The use of isosorbide mononitrate to enhance the portal pressure response to NSBBs has been almost abandoned since the advent of carvedilol.</li></ul>
                
            </div>
        </details>
        
        <details>
            <summary><strong>Simvastatin</strong></summary>
            <div>
                <ul><li>A multicenter double-anonymized RCT disclosed a reduced mortality when simvastatin was associated to propranolol and EVL in patients surviving an episode of AVH.</li><li>Simvastatin should be used with caution in patients with total bilirubin &gt; 3 mg/dL and used only at low doses (10–20 mg/day) in patients with CTP B–C because of the risk of rhabdomyolysis.</li></ul>
                
            </div>
        </details>
        
        <details>
            <summary><strong>TIPS</strong></summary>
            <div>
                <ul><li>TIPS when used as first-line therapy for secondary prophylaxis is associated with lower rebleeding rates compared with EVL + NSBB but has no impact on survival and is associated with higher rates of HE.</li><li>TIPS placement as first-line approach for secondary prophylaxis should be reserved for patients with other indications for TIPS, such as recurrent/refractory ascites, where it may improve survival.</li></ul>
                
            </div>
        </details>
        
        <details>
            <summary><strong>Guidance Statements</strong></summary>
            <div>
                <ul><li>Patients with variceal bleeding who do not fulfill the criteria for a preemptive TIPS and/or do not undergo TIPS during admission should undergo secondary prophylaxis with NSBB and endoscopic band ligation.</li><li>Use of TIPS for secondary prophylaxis can be considered in patients with additional indications for TIPS (e.g., refractory ascites).</li></ul>
                
            </div>
        </details>
        
            </div>
        </details>
        
        <details>
            <summary><strong>Gastric and Ectopic Varices</strong></summary>
            <div>
                <ul><li>Gastric varices (GV) are commonly classified according to the Sarin classification.</li><li>Varices along the lesser curvature (GOV1) share a natural history and can be treated comparably with esophageal varices.</li><li>Varices along the greater curvature (GOV2) and in the fundus (IGV1) are frequently referred to as cardiofundal or gastric fundal varices and have a different natural history than esophageal varices.</li></ul>
                
        <details>
            <summary><strong>Prevalence</strong></summary>
            <div>
                <ul><li>The prevalence of GV ranges between 17% and 25% among patients with cirrhosis that have not bled.</li><li>GV are more common among patients with prehepatic PH.</li><li>The presence of GV or ectopic varices indicate the presence of CSPH, but GV typically evolve and bleed at lower portal pressure than do esophageal varices.</li></ul>
                
            </div>
        </details>
        
        <details>
            <summary><strong>Prevention of Bleeding</strong></summary>
            <div>
                <ul><li>Patients with compensated cirrhosis with GV who have not experienced acute hemorrhage do have CSPH and should be evaluated for NSBB therapy with a goal of preventing rebleeding and decompensation.</li><li>The role of primary endoscopic or endovascular prophylaxis to prevent first hemorrhage in cardiofundal varices remains unclear.</li></ul>
                
            </div>
        </details>
        
        <details>
            <summary><strong>Ectopic Varices</strong></summary>
            <div>
                <ul><li>Ectopic varices, referring to varices located outside of the esophagus and proximal stomach, are uncommon but can cause substantial bleeding.</li><li>Data regarding management are limited to case series. No formal recommendations except for use of NSBB for CSPH can be suggested to prevent initial hemorrhage.</li></ul>
                
            </div>
        </details>
        
        <details>
            <summary><strong>Management of Initial and Recurrent Bleeding</strong></summary>
            <div>
                <ul><li>The initial management of acute gastric or ectopic variceal bleeding should follow the guidance for acute esophageal variceal bleeding.</li><li>Once endoscopy confirms the presence of bleeding cardiofundal or ectopic varices, the next management steps will be determined by center expertise and the patient’s vascular anatomy based on cross-sectional imaging.</li></ul>
                
            </div>
        </details>
        
        <details>
            <summary><strong>Endoscopic and Endovascular Options</strong></summary>
            <div>
                <ul><li>Various endoscopic and endovascular options are available including ECI, endoscopic cyanoacrylate with endoscopic coiling, endoscopic band ligation, BRTO, and TIPS.</li><li>Multidisciplinary assessment and management of patients is recommended.</li></ul>
                
            </div>
        </details>
        
        <details>
            <summary><strong>Salvage TIPS</strong></summary>
            <div>
                <ul><li>In the event that bleeding cannot be initially controlled with medical therapy, EVL, glue and/or transvenous obliteration, salvage TIPS creation is highly effective for initial bleed control with over 90% success rate in non-prehepatic PH.</li><li>TIPS placement for gastric or ectopic varices should be accompanied by simultaneous collateral obliteration or embolization.</li></ul>
                
            </div>
        </details>
        
        <details>
            <summary><strong>Prevention of Rebleeding</strong></summary>
            <div>
                <ul><li>Data around the prevention of rebleeding cardiofundal or ectopic varices are limited to small randomized trials and prospective single center cohorts.</li><li>Similar to esophageal variceal bleeding, a combination of a local therapy (endoscopic or endovascular) and portal pressure reduction with NSBB are recommended.</li></ul>
                
            </div>
        </details>
        
        <details>
            <summary><strong>Guidance Statements</strong></summary>
            <div>
                <ul><li>Patients with gastric or ectopic varices have CSPH and therefore the use of NSBBs should be considered for prevention of rebleeding and decompensation. These patients should be investigated for the presence of portal vein thrombosis.</li><li>Patients with high-risk cardiofundal (GOV2 or IGV1) varices ( ≥10 mm, red wale signs, CTP class B/C) who have contraindications or intolerance to NSBBs may be considered for primary prophylaxis with endoscopic cyanoacrylate injection (ECI).</li><li>Neither TIPS nor BRTO (or related obliterative techniques) are recommended to prevent first hemorrhage in patients with fundal varices that have not bled.</li><li>Initial management of bleeding gastric or ectopic varices should be identical to the management of bleeding esophageal varices, including vasoactive therapy, antimicrobials, conservative transfusion strategy, and endoscopic evaluation, within 12 hours.</li><li>Patients with bleeding gastric or ectopic varices should have contrast-enhanced cross-sectional imaging to define the anatomy of portosystemic collaterals or presence of venous thrombosis that would guide therapy.</li><li>In patients with acute hemorrhage from gastric (GOV2/IGV1) or ectopic varices, either endoscopic cyanoacrylate therapy, TIPS, or retrograde transvenous variceal embolization/obliteration can be considered first-line options. Retrograde obliteration is preferred when TIPS is contraindicated.</li><li>In patients who underwent ECI as the main therapy, the addition of NSBBs is recommended to prevent rebleeding, in absence of contraindications. Additionally, repeat endoscopic treatment at intervals every 2–4 weeks until obliteration and long-term surveillance should be performed.</li><li>Patients with bleeding GV caused by isolated splenic vein thrombosis should be evaluated for splenectomy, splenic vein stenting, or splenic artery embolization.</li></ul>
                
            </div>
        </details>
        
            </div>
        </details>
        
        <details>
            <summary><strong>Additional Topic Areas for Guidance</strong></summary>
            <div>
                <ul><li>Portal gastropathy: PHG and/or portal enteropathy, characterized by a “snake-skin” mosaic mucosal pattern with variable degrees of intraepithelial hemorrhage, is a common endoscopic observation in cirrhosis.</li><li>The condition results from increased portal pressure and submucosal vascular hyperemia resulting in associated mucosal venous and capillary ectasia.</li></ul>
                
        <details>
            <summary><strong>Grading Systems</strong></summary>
            <div>
                <ul><li>Several clinical grading systems have been proposed to identify features associated with high or low risk of complications, including the New Italian Endoscopic Club (NIEC) and Baveno III systems.</li><li>Consensus among grading systems is that the presence of intramucosal hemorrhage differentiates severe from mild PHG and that concomitant gastric antral vascular ectasia (GAVE) confers higher risk of hemorrhage.</li></ul>
                
            </div>
        </details>
        
        <details>
            <summary><strong>Prevalence</strong></summary>
            <div>
                <ul><li>The prevalence of PHG among patients with compensated cirrhosis ranges from 49% to 80%.</li><li>The development of PHG usually requires the presence of CSPH.</li></ul>
                
            </div>
        </details>
        
        <details>
            <summary><strong>Sequelae</strong></summary>
            <div>
                <ul><li>The primary sequelae of PHG are acute and chronic hemorrhage.</li><li>Acute bleeding from PHG is uncommon, occurring in 2.5%–5% of cases.</li><li>Chronic blood loss, typically defined as a 2 g/dL reduction in hemoglobin over a 6-month interval, occurs more commonly than acute bleeding, present in up to 4%–12% of cases.</li></ul>
                
            </div>
        </details>
        
        <details>
            <summary><strong>Management</strong></summary>
            <div>
                <ul><li>Low quality data support the use of intravenous octreotide, somatostatin, or terlipressin as a safe initial therapy to accelerate resolution and reduce need for transfusion.</li><li>Acute administration of NSBBs reduces gastric hyperemia and may also attenuate bleeding in acute PHG hemorrhage.</li><li>Most prospective studies suggest a potential prophylactic role for reduction of first or recurrent acute bleeding from PHG with NSBBs after exclusion of Helicobacter pylori as an alternative cause of mucosal granularity.</li></ul>
                
            </div>
        </details>
        
        <details>
            <summary><strong>PH-Related Polyps</strong></summary>
            <div>
                <ul><li>PH-related polyps can be found in the gastric antrum and occasionally in the duodenum in approximately 1%–10% of patients with cirrhosis, are predominantly hyperplastic, and carry negligible risk of malignant transformation.</li><li>PH-related polyps can contribute to chronic gastrointestinal bleeding in patients with cirrhosis, which may respond to NSBB or TIPS.</li></ul>
                
            </div>
        </details>
        
        <details>
            <summary><strong>Guidance Statements</strong></summary>
            <div>
                <ul><li>Patients with greater than mild PHG should be presumed to have CSPH and should therefore be considered for prophylactic NSBB to prevent decompensation; this intervention may also prevent hemorrhagic complications or iron-deficiency anemia from severe PHG.</li><li>In acute bleeding from severe PHG, vasoactive therapy (e.g., somatostatin, somatostatin analogs such as octreotide, or terlipressin if available) for 2–5 days at doses used for variceal bleeding should be considered.</li><li>NSBB are recommended to prevent rebleeding from PHG and PH-related polyps.</li><li>If bleeding from PHG becomes transfusion-dependent despite NSBB, TIPS placement should be considered.</li></ul>
                
            </div>
        </details>
        
            </div>
        </details>
        
        <details>
            <summary><strong>Varices in HCC</strong></summary>
            <div>
                <ul><li>Gastrointestinal bleeding is a known complication of anti–vascular endothelial growth factor therapies.</li><li>Variceal hemorrhage is an infrequent complication but in most series appears to be increased in the presence of portal vein thrombosis.</li></ul>
                
        <details>
            <summary><strong>Management</strong></summary>
            <div>
                <ul><li>Recent data suggest a poor correlation between endoscopic findings and variceal bleeding and no benefit of EBL over NSBB prophylaxis.</li><li>Among patients with acute variceal bleeding in HCC, rebleeding rates are increased relative to patients without HCC but secondary prophylaxis does significantly reduce this risk.</li></ul>
                
            </div>
        </details>
        
        <details>
            <summary><strong>Recommendation</strong></summary>
            <div>
                <ul><li>Prevention and treatment of AVH and hepatic decompensation in patients with HCC should follow the same principles as those for patients without HCC.</li><li>In the absence of contraindications, NSBB therapy is recommended for the primary prophylaxis for VH and prevention of decompensation in patients with HCC with CSPH (including varices).</li><li>In the presence of occlusive bland or malignant PVT, upper endoscopy is recommended to investigate the presence of gastroesophageal varices. If varices are detected, NSBB or endoscopic band ligation are recommended; preference is given to NSBB (including carvedilol) because of benefits beyond prevention of variceal hemorrhage.</li></ul>
                
            </div>
        </details>
        
            </div>
        </details>
        
        <details>
            <summary><strong>PH in Pregnancy</strong></summary>
            <div>
                <ul><li>Few data exist to guide systematic recommendations regarding the management of varices in cirrhotic PH in pregnancy.</li><li>AASLD guidance recommends that all patients with cirrhosis or noncirrhotic PH planning pregnancy undergo upper endoscopy within 1 year of conception; unscreened patients should undergo EGD early in the second trimester.</li></ul>
                
        <details>
            <summary><strong>Management</strong></summary>
            <div>
                <ul><li>Primary prophylaxis with NSBB or EBL for medium and large varices are recommended in pregnant patients with preference for EBL in the presence of cherry red spots or red wale signs.</li><li>In the setting of AVH, terlipressin should be avoided because of stimulation of uterine contraction, but somatostatin or octreotide may be used.</li><li>Case series exist documenting utilization of band ligation and TIPS for secondary prophylaxis or to control refractory variceal hemorrhage in pregnancy.</li></ul>
                
            </div>
        </details>
        
        <details>
            <summary><strong>Guidance Statements</strong></summary>
            <div>
                <ul><li>All patients with cirrhosis or noncirrhotic PH planning pregnancy should undergo upper endoscopy within 1 year of conception.</li><li>Unscreened pregnant patients with cirrhosis or noncirrhotic PH should undergo EGD early in the second trimester.</li></ul>
                
            </div>
        </details>
        
            </div>
        </details>
        
        <details>
            <summary><strong>Endoscopy Before TEE</strong></summary>
            <div>
                <ul><li>There is no evidence that TEE in patients with varices poses a significant risk of inducing variceal hemorrhage or that routine upper endoscopy prior to TEE significantly impacts patient outcomes.</li><li>As such, routine upper endoscopy prior to TEE is not recommended.</li></ul>
                
        <details>
            <summary><strong>Guidance Statement</strong></summary>
            <div>
                <ul><li>Routine upper endoscopy prior to TEE in patients with cirrhosis is not recommended.</li></ul>
                
            </div>
        </details>
        
            </div>
        </details>
        
        <details>
            <summary><strong>Preoperative TIPS Prior to Nonhepatic Operation</strong></summary>
            <div>
                <ul><li>Few data, and none emerging from RCTs, exist to confirm a benefit or risk-stratify patients with PH who may benefit from preoperative TIPS for elective nonhepatic operation.</li><li>In the absence of prospective studies, TIPS can be considered in patients on a case-by-case basis weighing the potential surgical benefits of TIPS with potential increased risk of HE and of worsening liver failure.</li></ul>
                
        <details>
            <summary><strong>Guidance Statement</strong></summary>
            <div>
                <ul><li>Preoperative TIPS can be considered on a case-by-case basis after careful consideration of potential surgical benefits relative to potential harms related to the procedure (encephalopathy, worsening of liver failure).</li></ul>
                
            </div>
        </details>
        
            </div>
        </details>
        
        <details>
            <summary><strong>Conclusions and Areas for Future Research</strong></summary>
            <div>
                <ul><li>The ability to noninvasively identify patients at high risk for decompensation and evidence that decompensation rates can be decreased with therapy enable a paradigm shift toward prevention of decompensation through NSBBs, disease control, and lifestyle modification.</li><li>Once decompensated, improved understanding of resuscitation and the role of preemptive TIPS should improve the survival of patients with AVH.</li></ul>
                
        <details>
            <summary><strong>Future Research</strong></summary>
            <div>
                <ul><li>Prospective validation of the “rule of 5” for the noninvasive selection of candidates for early initiation of nonselective beta-blockers (NSBBs) to prevent clinical decompensation and avoid screening endoscopy.</li><li>Systematic and cross-platform validation of cutpoints for magnetic resonance elastography, two-dimensional shear wave elastography, and point shear wave elastography for estimation of presence of clinically significant portal hypertension and high-risk varices.</li><li>Identification and validation of noninvasive modalities to monitor 10%–20% changes in HVPG.</li><li>Confirmation of clinical, Noninvasive Liver Disease Assessment (NILDA), and/or HVPG thresholds for clinical recompensation after which screening endoscopy or NSBB therapy is no longer required, allowing de-escalation of monitoring and treatment for portal hypertension.</li><li>External validation of the PREDESCI trial in additional populations (patients with NASH).</li><li>Definition of patients with portal hypertension who might benefit from an earlier decision for TIPS (i.e., after first bleeding; before major operation).</li><li>Quantification of the benefit from nutritional intervention in patients with cirrhosis and sarcopenia and/or frailty for prevention of first or further decompensation and/or improvement in survival.</li><li>Confirmation of the safety and effectiveness of statins in improving survival and/or preventing decompensation, further decompensation, and acute-on-chronic liver failure when used alone or coadministered with NSBBs, rifaximin, or other treatments.</li><li>Larger prospective studies of self-expanding esophageal stents to confirm role and refine utilization in acute variceal hemorrhage.</li></ul>
                
            </div>
        </details>
        
            </div>
        </details>
        
            </div>
        </details>
        
    </div>
    
</div>


<script>
function setMindmapLevel(level) {
    const allDetails = document.querySelectorAll('.mindmap details');

    // Close all
    allDetails.forEach(detail => detail.removeAttribute('open'));

    // Open based on depth
    allDetails.forEach(detail => {
        let depth = 0;
        let parent = detail.parentElement;
        while (parent && parent.tagName !== 'BODY') {
            if (parent.tagName === 'DETAILS') depth++;
            parent = parent.parentElement;
        }
        if (depth < level) detail.setAttribute('open', '');
    });
}

// Automatically open to level 1 on page load
window.addEventListener('DOMContentLoaded', () => {
    setMindmapLevel(1);
});

function dragElement(elmnt) {
    let pos1 = 0, pos2 = 0, pos3 = 0, pos4 = 0;

    const onMouseDown = (e) => {
        e.preventDefault();
        pos3 = e.clientX;
        pos4 = e.clientY;
        document.onmouseup = closeDragElement;
        document.onmousemove = elementDrag;
    };

    const elementDrag = (e) => {
        e.preventDefault();
        pos1 = pos3 - e.clientX;
        pos2 = pos4 - e.clientY;
        pos3 = e.clientX;
        pos4 = e.clientY;
        elmnt.style.top = (elmnt.offsetTop - pos2) + "px";
        elmnt.style.left = (elmnt.offsetLeft - pos1) + "px";
        elmnt.style.transform = "none"; // cancel centering transform
        elmnt.style.bottom = "auto"; // cancel fixed bottom
    };

    const closeDragElement = () => {
        document.onmouseup = null;
        document.onmousemove = null;
    };

    onMouseDown(event);
}
</script>


</body>
</html>
